Neuroimmunology of status epilepticus

[1]  E. Trinka,et al.  Management of Status Epilepticus, Refractory Status Epilepticus, and Super-refractory Status Epilepticus , 2022, Continuum.

[2]  D. Henshall,et al.  Increased expression of the ATP‐gated P2X7 receptor reduces responsiveness to anti‐convulsants during status epilepticus in mice , 2021, British journal of pharmacology.

[3]  S. Lattanzi,et al.  Unraveling the enigma of new‐onset refractory status epilepticus: a systematic review of aetiologies , 2021, European journal of neurology.

[4]  E. Aronica,et al.  CXCL1-CXCR1/2 signaling is induced in human temporal lobe epilepsy and contributes to seizures in a murine model of acquired epilepsy , 2021, Neurobiology of Disease.

[5]  T. Engel,et al.  ATP and adenosine—Two players in the control of seizures and epilepsy development , 2021, Progress in Neurobiology.

[6]  Q. Pittman,et al.  Increased Excitatory Synaptic Transmission Associated with Adult Seizure Vulnerability Induced by Early-Life Inflammation in Mice , 2021, The Journal of Neuroscience.

[7]  Takeshi Inoue,et al.  Intrathecal dexamethasone therapy for febrile infection‐related epilepsy syndrome , 2021, Annals of clinical and translational neurology.

[8]  R. Dingledine,et al.  Peripheral Myeloid Cell EP2 Activation Contributes to the Deleterious Consequences of Status Epilepticus , 2020, The Journal of Neuroscience.

[9]  R. Tulsawani,et al.  Loss of Protection by Antiepileptic Drugs in Lipopolysaccharide-primed Pilocarpine-induced Status Epilepticus is Mediated via Inflammatory Signalling , 2020, Neuroscience.

[10]  E. Elinav,et al.  Inflammasome activation and regulation: toward a better understanding of complex mechanisms , 2020, Cell Discovery.

[11]  F. Bertuzzi,et al.  Targeting CXCR1/2 Does Not Improve Insulin Secretion After Pancreatic Islet Transplantation: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial in Type 1 Diabetes , 2020, Diabetes Care.

[12]  Linda K. Han,et al.  A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer , 2020, Breast Cancer Research.

[13]  H. Butzkueven,et al.  Innate Immunity in the Central Nervous System: A Missing Piece of the Autoimmune Encephalitis Puzzle? , 2019, Front. Immunol..

[14]  K. Kothur,et al.  Etiology is the key determinant of neuroinflammation in epilepsy: Elevation of cerebrospinal fluid cytokines and chemokines in febrile infection‐related epilepsy syndrome and febrile status epilepticus , 2019, Epilepsia.

[15]  A. Vezzani,et al.  Neuroinflammatory pathways as treatment targets and biomarkers in epilepsy , 2019, Nature Reviews Neurology.

[16]  S. Barbieri,et al.  Therapeutic effect of Anakinra in the relapsing chronic phase of febrile infection–related epilepsy syndrome , 2019, Epilepsia open.

[17]  P. Olejniczak,et al.  Dexamethasone as Abortive Treatment for Refractory Seizures or Status Epilepticus in the Inpatient Setting , 2019, Journal of investigative medicine high impact case reports.

[18]  R. Dingledine,et al.  The COX-2/prostanoid signaling cascades in seizure disorders , 2018, Expert opinion on therapeutic targets.

[19]  K. Chu,et al.  Tocilizumab treatment for new onset refractory status epilepticus , 2018, Annals of neurology.

[20]  R. Miles,et al.  Microglial phenotypes in the human epileptic temporal lobe , 2018, Brain : a journal of neurology.

[21]  L. Capelle,et al.  Pannexin-1 channels contribute to seizure generation in human epileptic brain tissue and in a mouse model of epilepsy , 2018, Science Translational Medicine.

[22]  T. Loddenkemper,et al.  New‐onset refractory status epilepticus (NORSE) and febrile infection–related epilepsy syndrome (FIRES): State of the art and perspectives , 2018, Epilepsia.

[23]  E. Aronica,et al.  Review: Neuroinflammatory pathways as treatment targets and biomarker candidates in epilepsy: emerging evidence from preclinical and clinical studies , 2018, Neuropathology and applied neurobiology.

[24]  A. Vezzani,et al.  Inhibition of monoacylglycerol lipase terminates diazepam‐resistant status epilepticus in mice and its effects are potentiated by a ketogenic diet , 2018, Epilepsia.

[25]  A. Vezzani,et al.  High Mobility Group Box 1 is a novel pathogenic factor and a mechanistic biomarker for epilepsy , 2017, Brain, Behavior, and Immunity.

[26]  Benjamin J. Whalley,et al.  Therapeutic effects of cannabinoids in animal models of seizures, epilepsy, epileptogenesis, and epilepsy-related neuroprotection , 2017, Epilepsy & Behavior.

[27]  Shumei S. Sun,et al.  Plasma cytokines associated with febrile status epilepticus in children: A potential biomarker for acute hippocampal injury , 2017, Epilepsia.

[28]  E. Wirrell,et al.  Febrile infection‐related epilepsy syndrome treated with anakinra , 2016, Annals of neurology.

[29]  R. Dingledine,et al.  Inhibition of the prostaglandin E2 receptor EP2 prevents status epilepticus-induced deficits in the novel object recognition task in rats , 2016, Neuropharmacology.

[30]  K. Elisevich,et al.  Brain region and epilepsy-associated differences in inflammatory mediator levels in medically refractory mesial temporal lobe epilepsy , 2016, Journal of Neuroinflammation.

[31]  R. Ransohoff,et al.  Infiltrating monocytes promote brain inflammation and exacerbate neuronal damage after status epilepticus , 2016, Proceedings of the National Academy of Sciences.

[32]  Yu Wang,et al.  Up-regulation of CXCL1 and CXCR2 contributes to remifentanil-induced hypernociception via modulating spinal NMDA receptor expression and phosphorylation in rats , 2016, Neuroscience Letters.

[33]  Yi Wang,et al.  Interleukin-1 receptor is a target for adjunctive control of diazepam-refractory status epilepticus in mice , 2016, Neuroscience.

[34]  R. Wickström,et al.  Cytokine and Chemokine Expression in CSF May Differentiate Viral and Autoimmune NMDAR Encephalitis in Children , 2016, Journal of child neurology.

[35]  D. Henshall,et al.  ATPergic signalling during seizures and epilepsy , 2016, Neuropharmacology.

[36]  E. Aronica,et al.  Immunity and Inflammation in Epilepsy. , 2016, Cold Spring Harbor perspectives in medicine.

[37]  R. Dingledine,et al.  Immunity and inflammation in status epilepticus and its sequelae: possibilities for therapeutic application , 2015, Expert review of neurotherapeutics.

[38]  D. Henshall,et al.  P2X purinoceptors as a link between hyperexcitability and neuroinflammation in status epilepticus , 2015, Epilepsy & Behavior.

[39]  A. Zuckermann,et al.  A pilot study on reparixin, a CXCR1/2 antagonist, to assess safety and efficacy in attenuating ischaemia–reperfusion injury and inflammation after on‐pump coronary artery bypass graft surgery , 2015, Clinical and experimental immunology.

[40]  R. Dingledine,et al.  Therapeutic window for cyclooxygenase-2 related anti-inflammatory therapy after status epilepticus , 2015, Neurobiology of Disease.

[41]  Y. Takahashi,et al.  Intrathecal overproduction of proinflammatory cytokines and chemokines in febrile infection-related refractory status epilepticus , 2014, Journal of Neurology, Neurosurgery & Psychiatry.

[42]  M. Lythgoe,et al.  Dexamethasone exacerbates cerebral edema and brain injury following lithium-pilocarpine induced status epilepticus , 2014, Neurobiology of Disease.

[43]  Raymond Dingledine,et al.  Cyclooxygenase‐2 in epilepsy , 2014, Epilepsia.

[44]  J. Sandkühler,et al.  Neurogenic neuroinflammation: inflammatory CNS reactions in response to neuronal activity , 2013, Nature Reviews Neuroscience.

[45]  W. Löscher,et al.  Pharmacological blockade of IL-1β/IL-1 receptor type 1 axis during epileptogenesis provides neuroprotection in two rat models of temporal lobe epilepsy , 2013, Neurobiology of Disease.

[46]  D. Henshall,et al.  P2X receptors as targets for the treatment of status epilepticus , 2013, Front. Cell. Neurosci..

[47]  S. Cichon,et al.  TLR4, ATF-3 and IL8 inflammation mediator expression correlates with seizure frequency in human epileptic brain tissue , 2013, Seizure.

[48]  C. Mooney,et al.  Increased neocortical expression of the P2X7 receptor after status epilepticus and anticonvulsant effect of P2X7 receptor antagonist A‐438079 , 2013, Epilepsia.

[49]  R. Dingledine,et al.  Prostaglandin receptor EP2 in the crosshairs of anti-inflammation, anti-cancer, and neuroprotection. , 2013, Trends in pharmacological sciences.

[50]  H. Chugani,et al.  Successful surgical treatment of an inflammatory lesion associated with new-onset refractory status epilepticus. , 2013, Neurosurgical focus.

[51]  Q. Pittman,et al.  Increased excitability and molecular changes in adult rats after a febrile seizure , 2013, Epilepsia.

[52]  Masahito Hayashi,et al.  An immunologic case study of acute encephalitis with refractory, repetitive partial seizures , 2012, Brain and Development.

[53]  Q. Pittman,et al.  Cytokines and brain excitability , 2012, Frontiers in Neuroendocrinology.

[54]  Nan Zhang,et al.  Elevated interleukin-8 enhances prefrontal synaptic transmission in mice with persistent inflammatory pain , 2012, Molecular pain.

[55]  Annamaria Vezzani,et al.  High-mobility group box-1 impairs memory in mice through both toll-like receptor 4 and Receptor for Advanced Glycation End Products , 2011, Experimental Neurology.

[56]  D. Nomura,et al.  Endocannabinoid Hydrolysis Generates Brain Prostaglandins That Promote Neuroinflammation , 2011, Science.

[57]  Annamaria Vezzani,et al.  Status epilepticus-induced pathologic plasticity in a rat model of focal cortical dysplasia. , 2011, Brain : a journal of neurology.

[58]  T. Bártfai,et al.  IL-1 receptor/Toll-like receptor signaling in infection, inflammation, stress and neurodegeneration couples hyperexcitability and seizures , 2011, Brain, Behavior, and Immunity.

[59]  D. Janigro,et al.  Efficacy of Anti-Inflammatory Therapy in a Model of Acute Seizures and in a Population of Pediatric Drug Resistant Epileptics , 2011, PloS one.

[60]  K. Frei,et al.  Brain Infiltration of Leukocytes Contributes to the Pathophysiology of Temporal Lobe Epilepsy , 2011, The Journal of Neuroscience.

[61]  M. Lamkanfi,et al.  HMGB1 release by inflammasomes , 2011, Virulence.

[62]  R. Kohman,et al.  The effects of age on lipopolysaccharide-induced cognitive deficits and interleukin-1β expression , 2011, Behavioural Brain Research.

[63]  Quentin J. Pittman,et al.  Contributions of peripheral inflammation to seizure susceptibility: Cytokines and brain excitability , 2010, Epilepsy Research.

[64]  R. Sapolsky,et al.  The Stressed CNS: When Glucocorticoids Aggravate Inflammation , 2009, Neuron.

[65]  R. Raedt,et al.  Effects of vagus nerve stimulation on pro- and anti-inflammatory cytokine induction in patients with refractory epilepsy , 2009, Journal of Neuroimmunology.

[66]  Mark R Hutchinson,et al.  The cortical innate immune response increases local neuronal excitability leading to seizures. , 2009, Brain : a journal of neurology.

[67]  I. Najm,et al.  Antagonism of peripheral inflammation reduces the severity of status epilepticus , 2009, Neurobiology of Disease.

[68]  Q. Pittman,et al.  Neonatal inflammation produces selective behavioural deficits and alters N‐methyl‐d‐aspartate receptor subunit mRNA in the adult rat brain , 2008, The European journal of neuroscience.

[69]  Eleonora Aronica,et al.  Innate and adaptive immunity during epileptogenesis and spontaneous seizures: Evidence from experimental models and human temporal lobe epilepsy , 2008, Neurobiology of Disease.

[70]  M. Sayyah,et al.  The bacterial endotoxin lipopolysaccharide enhances seizure susceptibility in mice: involvement of proinflammatory factors: nitric oxide and prostaglandins , 2003, Neuroscience.

[71]  R. Sapolsky,et al.  Novel glucocorticoid effects on acute inflammation in the CNS , 2003, Journal of neurochemistry.

[72]  S. Garattini,et al.  Inflammatory cytokines and related genes are induced in the rat hippocampus by limbic status epilepticus , 2000, The European journal of neuroscience.

[73]  M. Walker,et al.  Targeting oxidative stress improves disease outcomes in a rat model of acquired epilepsy. , 2019, Brain : a journal of neurology.